Investors

W= all Street Stockwatch
W= asatch Pharmaceuticals: Company Update

Special Corporat= e Update WSCH

Company Name = Wasatch Pharmaceuticals (OTCBB: WSCH)

Current Price= = $0.007
52-Week High<= /TD> = $1.95
52-Week Low <= FONT face=3DVerdana color=3D#800000 size=3D2>$0.0045

News from Wasatch Pharmaceutical = (OTCBB: WSCH) is hard to come by lately. Gary Heesch, CEO of Was= atch, doesn't buy the idea that a press release every day is productive.= He feels "it is usually perceived as an effort to over- promote= the stock." But what about the future of WSCH? Why sho= uld anyone buy or hold their stock with no news?

Mr. Heesch feels that past= news releases and their record of Company accomplishments speak for themselves. For example, Wasatch, now in its 18th year of= research, has produced skin care products for the treatment of= most common skin disorders. This puts them years ahead of the competition.

In the last 12 months, WSCH has a= ddressed a whole new dimension in preparation for launching its products i= nto the worldwide marketplace, so that millions of people will fin= ally have access to therapies that allow them to remedy their skin diso= rders and live more normal lives. This preparation involved:

(= 1) A new management team with impressive individual records of crea= ting billions of dollars in revenue for Oracle, Bausch & Lomb, and = Warner Lambert.

(2) The establishment of a new AISC Distrib= ution Center that is fully inventoried with products ready for shipment.

(3) Establishing beautiful corporate offices separate from the company's clinic.

(4) Relocation <= /B>of the American Institue of Skin Care clinic to a facility designed t= o be the prototype for future clinics.

To cap off the last 12 mo= nths, patents were filed for five new products that will be packa= ged and ready for release to physicians and hospitals this year. = All of these accomplishments translate into a variety of activites and= relationships that will insure the growth and stability of WSCH.

When pressed to reveal this year's plans, Mr. Hee= sch wants to reserve the substance of these activities until they a= re completed and tucked away. He did say that existing acti= vities and plans include the acquisition of existing medical clini= cs, ongoing discussion for foreign licensing, conversations wit= h groups of physicians that can represent as many as 2,000 physic= ians converting their patients to Wasatch products for their skin c= are problems, and also a possible merger that will expand WSCH's sphere of influence in the medical community.

As these activities come to fruition, they will be disclosed to WSCH shareholders and the = public in detail. Unlike many companies struggling with today's economy,<= B> Wasatch Pharmaceutical is alive and well and working towards a productive future.

Stay tuned for plenty more to come from WSCH.

To be removed from future mailings, plea= se respond
to this email with "Remove" in the subject line

DISCLAIMER:
Information within this= email contains "forward looking statements" within the meaning of Section = 27A of the Securities Act of 1933 and Section 21B of the Securities Exchang= e Act of 1934. Any statements that express or involve discussions with res= pect to predictions, expectations, beliefs, plans, projections, objective= s, goals, assumptions or future events or performance are not statement= s of historical fact and may be "forward looking statements."

Forw= ard looking statements are based on expectations, estimates and projecti= ons at the time the statements are made that involve a number of risks= and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking stateme= nts in this action may be identified through the use of words such as "proj= ects", "foresee", "expects", "will," "anticipates," "estimates," "believes," "understands" or that by statements indicating certain a= ctions "may," "could," or "might" occur. All information provided wit= hin this email pertaining to investing, stocks, securities must be under= stood as information provided and not investment advice. Emerging Growth S= tock Alert advises all readers and subscribers to seek advice from a= registered professional securities representative before deciding to= trade in stocks featured within this email. None of the material wit= hin this report shall be construed as any kind of investment advice.
=
In compliance with the Securities Act of 1933, Section17(b), Emerging G= rowth Stock Alert discloses the receipt of ten million unrestricted shares= of WSCH from a third party for the publication of this report and additional services re= lated to WSCH. Be aware of an inherent conflict of interest resulting from su= ch compensation due to our intent to profit from the sale of these shares. All factual information in this report was gather= ed from public sources, including but not limited to SEC filings, Compa= ny Press Releases, and the company's website at wasatchpharm.com. Emerging Growth Stock Alert= believes this information to be reliable but can make no guarantee a= s to its accuracy or completeness. Use of the material within this email constitutes your acceptance of these terms.

To be removed from future mailings, plea= se respond
to this email with "Remove" in the subject line